V
Vertex Pharmaceuticals Incorporated
VRTX · NASDAQ · USD
Historical Earnings
| Quarter | Reported | EPS est | EPS act | Surprise | Rev est | Rev act | Surprise | Reaction |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | 4.74 | 4.73 | −0.2% | $3.2B | $3.3B | +3.2% | +1.70% |
| Q1 2026 | May 4, 2026 | 4.24 | 4.47 | +5.4% | $3.0B | $3.0B | −0.2% | −1.28% |
| Q4 2025 | Feb 12, 2026 | 5.11 | 5.03 | −1.6% | $3.2B | $3.2B | +0.2% | +5.69% |
| Q3 2025 | Nov 3, 2025 | 4.57 | 4.80 | +5.0% | $3.1B | $3.1B | +0.6% | −1.02% |
| Q2 2025 | Aug 4, 2025 | 4.29 | 4.52 | +5.4% | $2.9B | $3.0B | +2.0% | −20.60% |
| Q1 2025 | May 5, 2025 | 4.25 | 4.06 | −4.5% | $2.9B | $2.8B | −3.2% | −10.03% |
| Q4 2024 | Feb 10, 2025 | 4.02 | 3.98 | −1.0% | $2.8B | $2.9B | +4.6% | −3.14% |
| Q3 2024 | Nov 4, 2024 | 4.14 | 4.38 | +5.8% | $2.7B | $2.8B | +3.2% | +5.73% |
Detailed View
Q3 2026Nov 2, 2026Q2 2026Aug 3, 2026+1.70%Q1 2026May 4, 2026−1.28%Q4 2025Feb 12, 2026+5.69%Q3 2025Nov 3, 2025−1.02%Q2 2025Aug 4, 2025−20.60%Q1 2025May 5, 2025−10.03%Q4 2024Feb 10, 2025−3.14%Q3 2024Nov 4, 2024+5.73%Q2 2024Aug 1, 2024Q1 2024May 6, 2024Q4 2023Feb 5, 2024
2026 Q2 Metrics
| Metric | Estimate | Actual | Surprise | Y/Y |
|---|---|---|---|---|
| Revenue | $3.2B | $3.3B | Beat +3.20% | +12.5% |
| EPS | 4.74 | 4.73 | Miss −0.21% | +4.6% |
| Diluted EPS (GAAP) | — | 4.31 | — | +8.0% |
Documents
- Earnings call transcript — Q2 2026Transcript · Aug 3, 2026 · 44 speaker turns
- 8-K — Q2 20268-K · Sep 1, 2026 · sec.gov
- 10-Q — Q2 202610-Q · Aug 4, 2026 · sec.gov
- 8-K — Q2 20268-K · Aug 3, 2026 · sec.gov
- 8-K — Q2 20268-K · Jul 7, 2026 · sec.gov